84,445 Moderna, Inc. $MRNA Shares Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. lifted its position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 18.9% in the third quarter, HoldingsChannel.com reports. The firm owned 531,893 shares of the company’s stock after purchasing an additional 84,445 shares during the period. Russell Investments Group Ltd.’s holdings in Moderna were worth $102,551,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of MRNA. BlackRock Inc. purchased a new position in Moderna during the 2nd quarter valued at about $2,142,877,000. Theleme Partners LLP bought a new position in Moderna during the 2nd quarter valued at approximately $564,272,000. Wellington Management Group LLP raised its position in Moderna by 4.4% during the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after purchasing an additional 103,977 shares during the last quarter. First Trust Advisors LP lifted its holdings in Moderna by 59.3% in the 1st quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock worth $121,549,000 after buying an additional 891,072 shares during the period. Finally, Merck & Co. Inc. purchased a new stake in Moderna in the 2nd quarter worth approximately $161,642,545. 75.33% of the stock is owned by institutional investors.

Moderna Price Performance

NASDAQ:MRNA opened at $223.37 on Monday. The firm’s 50-day moving average price is $201.67 and its 200-day moving average price is $96.41. The company has a market capitalization of $90.38 billion, a PE ratio of -31.46 and a beta of 1.16. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $280.80.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. During the same period last year, the business earned ($0.51) EPS. Moderna’s quarterly revenue was up 29.2% compared to the same quarter last year. On average, equities analysts predict that Moderna, Inc. will post -5.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Argus upgraded Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research report on Friday, August 28th. Royal Bank Of Canada restated a “sector perform” rating and set a $130.00 target price on shares of Moderna in a report on Wednesday, August 19th. JPMorgan Chase & Co. raised their target price on shares of Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research report on Friday, August 21st. Loop Capital set a $135.00 price target on shares of Moderna in a research note on Wednesday, August 19th. Finally, Bank of America raised their price objective on shares of Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Six investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $113.75.

Read Our Latest Research Report on MRNA

Insiders Place Their Bets

In other Moderna news, CFO Jamey Mock sold 34,836 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 39,145 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total value of $8,640,084.40. Following the transaction, the president directly owned 1,636,565 shares of the company’s stock, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is currently owned by company insiders.

Moderna Company Profile

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Recommended Stories

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.